Lorlatinib/lorlatinib’s domestic launch time and its significance in the treatment of lung cancer

Lorlatinib is a third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) leading the way. Its debut in China will have a profound impact on the field of domestic lung cancer treatment, especially on patients with ALK mutation-positive non-small cell lung cancer (NSCLC).

As early asIn April 2021, the domestic marketing application of lorlatinib was successfully approved, which indicates that this revolutionary drug is about to shine in the Chinese market. The long wait is finally over. On April 30, 2022, lorlatinib officially launched on the Chinese market, bringing hope to many long-awaited lung cancer patients and their families.

The emergence of lorlatinib has quickly won widespread recognition in ALK-positive NSCLC patients. Its excellent efficacy can not only effectively curb the further development and spread of tumors, but also significantly extend the progression-free survival of patients, which means that patients can live longer and with higher quality of life. It is worth mentioning that lorlatinib also performs well in the treatment of brain metastases from lung cancer, providing a new treatment strategy for patients at risk of brain metastases.

What is gratifying is that lorlatinib was included in the national medical insurance directory soon after it was launched, which is undoubtedly a great benefit to the majority of patients. For eligible patients, they can now use their insurance to reimburse the drug, significantly reducing the financial burden and making continued treatment more feasible.

In general, the official launch of lorlatinib in the Chinese market on April 30, 2022, not only provides a new treatment path for ALK-positive NSCLC patients, but also marks a major progress in the field of lung cancer treatment. Looking to the future, as medical insurance support policies continue to strengthen, we have reason to believe that lorlatinib will bring hope of life and improve the quality of life to more patients.